Bill Gates

Forbes  Aug 30  Comment 
You might be connected to Bill Gates, Mark Cuban, or another idolized success, but if the relationship isn?t strong enough to help you out, is it really that valuable? It?s important to not get distracted by aiming for relationships with big-name...  Aug 13  Comment 
Read full story for latest details.
Clusterstock  Aug 10  Comment 
There's a new way to edit genes, and companies want to use it to treat disease. Editas Medicine, a company aimed at providing technologies that enable scientists to tweak our genes, just raised $120 million to continue studying a novel new...
Forbes  Aug 10  Comment 
Four years ago, the protein called CRISPR-Cas9, an enzyme that bacteria use to attack viruses that infect them, was unknown to humans. Now it is ubiquitous in science labs as the most efficient way of cutting-and-pasting DNA yet invented. Wired...
FierceBiotech  Aug 10  Comment 
Editas quickly emerged as one of the first biotech upstarts with potentially game-changing gene editing technology in its hands. Now it's rounded up a $120 million megaround to speed its way through the next two years of research, setting up its...
Financial Times  Aug 9  Comment 
For every Bill Gates you needed a Steve Ballmer to leap around sweating and screaming
Forbes  Aug 4  Comment 
I spoke recently to Brad Silverberg of Fuel Capital who led the Windows 95 and Internet Explorer teams at Microsoft. We discussed what made Microsoft so great back in the day and what it was like to work for Gates and Ballmer.
MarketWatch  Jul 31  Comment 
So today, no mere homers, Bill Gates and Warren Buffett must hit grand slams to get in philanthropy’s Hall of Fame. So what would a real grand slam homer look like for two of the highest-paid hitters in the Billionaires Big League?
The Economic Times  Jul 31  Comment 
Gates sold more than $717 million of Microsoft stock this year, according to, and he wasn't the only one to turn his equity into cash.  Jul 24  Comment 
Read full story for latest details.


Related Articles

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki